NEW YORK, April 16, 2013 /PRNewswire/ -- VentriNova, a cardiac regenerative medicine biotechnology company, announced today that Dr. Hina Chaudhry, Founder, will be presenting VentriNova at the TEDMED 2013 conference April 16-19, 2013 as part of the TEDMED Hive for the most innovative startup companies in healthcare. The meeting takes place at the John F. Kennedy Center for the Performing Arts in Washington, D.C., and it will also be available online at www.TEDMED.com.
Dr. Chaudhry has been named a TEDMED Innovation Scholar and will present VentriNova’s vision for cardiac regeneration based on the modulation of the heart’s intrinsic repair pathways that lie dormant after birth in humans. The presentation will include details of the company’s compelling pre-clinical data in small and large animal models as well as its translational strategy towards developing clinical therapies and preparing for a human clinical trial. Corporate growth and financing plans will also be discussed.
“The Hive provides an exciting opportunity to spread the word about innovations that can truly make a difference in healthcare, and I am honored that VentriNova was selected to participate in the program’s inaugural event,” said Dr. Chaudhry. “I am looking forward to sharing the results of many years of research demonstrating that modulation of the cyclin A2 gene, which is normally silenced in mammalian hearts after birth, has been proven to stimulate growth of new heart muscle cells.”
About TEDMED and The Hive
TEDMED is a multi-disciplinary community of innovators and leaders who share a common determination to create a better future in health and medicine. Once a year at The Kennedy Center in Washington, DC, TEDMED curates an unusual and provocative program on the Opera House stage. At TEDMED 2013, 50 transformative innovations and the entrepreneurs, from varied fields both inside and outside health and medicine, that represent them will be part of “The Hive” in association with the Startup Health Network. At The Hive, incubators and accelerators, government-run programs, academic specialists, independent start-ups and labs run by Fortune 500 companies will come together to share and to discover important drivers of innovation.
About VentriNova, Inc.
VentriNova is a preclinical stage regenerative medicine company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart muscle cells. No technology on the market or in clinical development, including stem cell-based technologies and other regenerative medicine applications, has the ability to grow new heart muscle cells in the diseased heart. VentriNova’s pioneering science and technology is centered on development of biologic and small molecule regulators of the cyclin A2 gene the key switch mediating heart cell division. VentriNova’s technology has demonstrated that modulation of the cyclin A2 gene stimulates endogenous growth of new myocytes (heart muscle cells) and significantly enhances cardiac contractile function in both small and large animals. Led by a world-class team, VentriNova is privately held and backed by Broadview Ventures and NIH funding. For more information, please visit www.ventrinovainc.com.
Media and Investor Contact:
Michelle Linn
Linnden Communications
Phone: 774-696-3803
Email: michelle@linndencom.com
SOURCE VentriNova, Inc.
